prikaz prve stranice dokumenta Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide
  Preuzmi
PDF 2.34 MB
Znanstveni rad - Izvorni znanstveni rad
Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide
Frontiers in Molecular Biosciences, 8 (2021); 745360. https://doi.org/10.3389/fmolb.2021.745360
Pietri, Gian Pietro; Tontini, Marta; Brogioni, Barbara; Oldrini, Davide; Robakiewicz, Stefania; Henriques, Pedro; Calloni, Ilaria; Abramova, Vera; Santini, Laura; Malić, Suzana; Miklić, Karmela; Lisnić, Berislav; Bertuzzi, Sara; Unione, Luca; Balducci, Evita; de Ruyck, Jérôme; Romano, Maria Rosaria; Jimenez-Barbero, Jesus; Bouckaert, Julie; Jonjić, Stipan; Roviš, Tihana Lenac; Adamo, Roberto Više autora...

Citiranost:
,
Citirajte ovaj rad

Pietri, G. P., Tontini, M., Brogioni, B., Oldrini, D., Robakiewicz, S., Henriques, P. ... Adamo, R. (2021). Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide. Frontiers in Molecular Biosciences, 8.. doi: 10.3389/fmolb.2021.745360

Pietri, Gian Pietro, et al. "Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide." Frontiers in Molecular Biosciences, vol. 8, 2021. https://doi.org/10.3389/fmolb.2021.745360

Pietri, Gian Pietro, Marta Tontini, Barbara Brogioni, Davide Oldrini, Stefania Robakiewicz, Pedro Henriques, Ilaria Calloni, et al. "Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide." Frontiers in Molecular Biosciences 8 (2021). https://doi.org/10.3389/fmolb.2021.745360

Pietri, G. P., et al. (2021) 'Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide', Frontiers in Molecular Biosciences, 8. doi: 10.3389/fmolb.2021.745360

Pietri GP, Tontini M, Brogioni B, Oldrini D, Robakiewicz S, Henriques P, i sur.. Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide. Frontiers in Molecular Biosciences [Internet]. 14.10.2021. [pristupljeno 25.02.2025.];8. doi: 10.3389/fmolb.2021.745360

G. P. Pietri, et al., "Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide", Frontiers in Molecular Biosciences, vol. 8, Listopad 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:507469. [Citirano: 25.02.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:507469
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide
AutorGian Pietro Pietri
AutorMarta Tontini
AutorBarbara Brogioni
AutorDavide Oldrini
AutorStefania Robakiewicz
AutorPedro Henriques
AutorIlaria Calloni
AutorVera Abramova
AutorLaura Santini
AutorSuzana Malić
AutorKarmela Miklić
AutorBerislav Lisnić
AutorSara Bertuzzi
AutorLuca Unione
AutorEvita Balducci
AutorJérôme de Ruyck
AutorMaria Rosaria Romano
AutorJesus Jimenez-Barbero
AutorJulie Bouckaert
AutorStipan Jonjić
AutorTihana Lenac Roviš
AutorRoberto Adamo
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Centar za proteomiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Despite the considerable progress toward the eradication of meningococcal disease with the introduction of glycoconjugate vaccines, previously unremarkable serogroup X has emerged in recent years, recording several outbreaks throughout the African continent. Different serogroup X polysaccharide-based vaccines have been tested in preclinical trials, establishing the principles for further improvement. To elucidate the antigenic determinants of the MenX capsular polysaccharide, we generated a... Više monoclonal antibody, and its bactericidal nature was confirmed using the rabbit serum bactericidal assay. The antibody was tested by the inhibition enzyme-linked immunosorbent assay and surface plasmon resonance against a set of oligosaccharide fragments of different lengths. The epitope was shown to be contained within five to six α-(1–4) phosphodiester mannosamine repeating units. The molecular interactions between the protective monoclonal antibody and the MenX capsular polysaccharide fragment were further detailed at the atomic level by saturation transfer difference nuclear magnetic resonance (NMR) spectroscopy. The NMR results were used for validation of the docking analysis between the X-ray crystal structure of the antibody (Fab fragment) and the modeled hexamer oligosaccharide. The antibody recognizes the MenX fragment by binding all six repeating units of the oligosaccharide hydrogen bonding, salt bridges, and hydrophobic interactions. studies demonstrated that conjugates containing five to six repeating units can produce high functional antibody levels. These results provide an insight into the molecular basis of MenX vaccine-induced protection and highlight the requirements for the epitope-based vaccine design. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Molecular Biosciences
Brojčani podacivol. 8, 745360
e-ISSN2296-889X
DOIhttps://doi.org/10.3389/fmolb.2021.745360
URN:NBNurn:nbn:hr:184:507469
Datum objave publikacije2021-10-14
ProjektŠifra: 675671
Naziv (engleski): A training network for the rational design of the next generation of well-defined glycoconjugate vaccines
Kratica: GLYCOVAX
Pravna nadležnost: eu
Financijer: EC
Linija financiranja: H2020
ProjektŠifra: KK.011.1.01.0006
Naziv (engleski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: ERDF
Linija financiranja: MZOS 15% - ERDF 85%
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fmolb.2021.745360/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-12-06 08:55:27
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.